Personalized Medicine for Parkinson's Disease New Concepts and Future of Individualized Management

• Andere auteurs: Titova, Nataliya (Redacteur), Chaudhuri, K. Ray (Redacteur)
• Formaat: Elektronisch Hoofdstuk
• Taal: Engels
• Gepubliceerd in: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
• Onderwerpen: Medicine; Neurology & clinical neurophysiology; Parkinson's disease; movement disorders; periodontitis; periodontal disease; hematologic tests; Vitamin D; oral health; Parkinson's Disease; cognition; GABAergic signaling; cerebellum; MRS; response inhibition; non-motor symptoms; carer stress; older persons with Parkinson's disease; education; lifestyle behaviours; diet; cross-sectional; population study; neurological disorders; precision medicine; genetics; clinical trials; Parkinson's disease (PD); cognitive rehabilitation; intervention; deep brain stimulation; levodopa-carbidopa intestinal gel; apomorphine; radiofrequency; focused ultrasound; induced pluripotent stem cells; cell therapy; gene therapy; personalized medicine; advanced Parkinson's disease (APD); apomorphine subcutaneous infusion therapy; pain; intrajejunal; levodopa; motor and non-motor symptoms; PKG (KinetiGrap); rehabilitation; device-aided therapies; personalised medicine; Alzheimer's disease; clinical trial; impulsive-compulsive disorders (ICD); dopaminergic therapy; genetic markers; pharmacogenetic; polymorphisms; insomnia; sleep quality; assessment; young onset Parkinson's (YOPD); Emiratis; expatriate; genetic; epigenetics; societal impact; device aided therapies; quality of life; non motor symptoms; n/a
• Online toegang: DOAB: download the publication; DOAB: description of the publication

Personalized medicine for Parkinson's disease is a growing and emerging concept in light of recent recognition that Parkinson's is a syndromic condition affecting multiple neurotransmitter systems, as well as brain and extracranial structures. The clinical expression is, thus, heterogeneous, and presentation age can range from the 30s to the 90s, with PD in older patients being associated with significant neuropathological comorbidity as well, involving not just misfolded alpha synuclein deposition but also amyloid and tau. Traditional and largely guideline-driven "one size fits all" management strategies adopted in clinical practice are, therefore, often inadequate in holistic management of a patient, particularly when aspects of motor and nonmotor symptoms are taken into consideration. In this supplement of JPM, we present a selection of papers which address several possible strands of personalized medicine in PD, ranging from genomic precision medicine to digital "checklists" to ensure delivery of holistic personalized medicine involving nonpharmacological strategies, as well. We are soliciting any papers addressing biomarkers, genetics and pharmacogenetics, treatment or complementary therapies for personalized or individualized treatment for PD.